An Antitumor Cellular Vaccine Based on a Mini-Membrane IgE

The IgE-mediated immune system activation can be redirected to combat tumors. Mouse and human IgE have been shown to provide a potent adjuvant effect in antitumor vaccination, with a crucial role played by FcεRI. This effect results from T cell-mediated adaptive immune response. Modified vaccinia virus Ankara (MVA) has been used to infect IgE-loaded tumor cells. These results led to a shift toward a highly safe protocol employing membrane IgE (mIgE), thus eliminating any possible anaphylactogenicity caused by circulating IgE. Evidence that human mIgE and a truncated version lacking IgE Fabs (tmIgE) bind and activate FcεRI has been fundamental and forms the core of this report. Human tmIgE has been engineered into a recombinant MVA (rMVA-tmIgE), and the expression of tmIgE and its transport to the surface of rMVA-tmIgE–infected cells has been detected by Western blot and cytofluorimetry, respectively. FcεRI activation by tmIgE has been confirmed by the release of β-hexosaminidase in a cell-to-cell contact assay using human FcεRI-transfected RBL-SX38 cells. The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcεRIα−/− human FcεRIα+ mice, with results indicating a level of protection comparable to that obtained using soluble human IgE tumor cell loading. The rMVA-tmIgE vector represents a device that suits safe IgE-based antitumor vaccines, harboring the possibility to couple tmIgE with other gene insertions that might enhance the antitumor effect, thus bringing the field closer to the clinics.

[1]  R. Owens,et al.  Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI , 2011, Nature Structural &Molecular Biology.

[2]  A. Liston,et al.  Understanding the genetic regulation of IgE production. , 2010, Blood reviews.

[3]  D. Chi,et al.  Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective , 2010, Clinical and molecular allergy : CMA.

[4]  A. Agresti,et al.  The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. , 2010, Journal of virological methods.

[5]  D. Dombrowicz,et al.  Antitumor IgE Adjuvanticity: Key Role of FcεRI1 , 2009, The Journal of Immunology.

[6]  C. Staib,et al.  Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. , 2009, Journal of virological methods.

[7]  A. Riemer,et al.  AllergoOncology: the role of IgE‐mediated allergy in cancer , 2008, Allergy.

[8]  B. Wolff,et al.  The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. , 2008, The Journal of clinical investigation.

[9]  J. Bonnefoy,et al.  Clinical development of MVA-based therapeutic cancer vaccines , 2008, Expert review of vaccines.

[10]  M. Pincus,et al.  Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody‐dependent cell‐mediated cytotoxicity against pancreatic cancer cells , 2008, Clinical and experimental immunology.

[11]  B. Sutton,et al.  IgE in allergy and asthma today , 2008, Nature Reviews Immunology.

[12]  Martin Knapp,et al.  Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.

[13]  G. McFadden,et al.  Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development , 2005, Cytotechnology.

[14]  F. Codazzi,et al.  Membrane IgE Binds and Activates FcεRI in an Antigen-Independent Manner1 , 2005, The Journal of Immunology.

[15]  Christopher R. Jones,et al.  Sex increases the efficacy of natural selection in experimental yeast populations , 2005, Nature.

[16]  Chung-I Wu,et al.  The Normal Function of a Speciation Gene, Odysseus, and Its Hybrid Sterility Effect , 2004, Science.

[17]  M. Shlomchik,et al.  The B Cell Receptor Itself Can Activate Complement to Provide the Complement Receptor 1/2 Ligand Required to Enhance B Cell Immune Responses In Vivo , 2003, The Journal of experimental medicine.

[18]  L. Vangelista.  Current Progress in the Understanding of IgE-FcεRI Interaction , 2003, International Archives of Allergy and Immunology.

[19]  J. Morrow,et al.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. , 2003, The Journal of clinical investigation.

[20]  R. Owens,et al.  The crystal structure of IgE Fc reveals an asymmetrically bent conformation , 2002, Nature Immunology.

[21]  J. Sepúlveda,et al.  Membrane Immunoglobulins Are Stabilized by Interchain Disulfide Bonds Occurring within the Extracellular Membrane-Proximal Domain , 2001 .

[22]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[23]  D. Dombrowicz,et al.  Human Eosinophils and Human High Affinity IgE Receptor Transgenic Mouse Eosinophils Express Low Levels of High Affinity IgE Receptor, but Release IL-10 upon Receptor Activation , 2001, The Journal of Immunology.

[24]  J. Schlom,et al.  IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. , 2001, Cancer research.

[25]  T. Jardetzky,et al.  Structure of the human IgE-Fc C epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains. , 2000, Immunity.

[26]  T. Jardetzky,et al.  Structure of the Human IgE-Fc Cε3-Cε4 Reveals Conformational Flexibility in the Antibody Effector Domains , 2000 .

[27]  C. Staib,et al.  Transient host range selection for genetic engineering of modified vaccinia virus Ankara. , 2000, BioTechniques.

[28]  A. Corti,et al.  Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. , 1999, Cancer research.

[29]  D. Dombrowicz,et al.  Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. , 1998, Immunity.

[30]  O. Burrone,et al.  Mammalian cell expression of dimeric small immune proteins (SIP). , 1997, Protein engineering.

[31]  D. Dombrowicz,et al.  Anaphylaxis mediated through a humanized high affinity IgE receptor. , 1996, Journal of immunology.

[32]  J. Kinet,et al.  High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. , 1996, Journal of immunology.

[33]  D. Dombrowicz,et al.  Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor α chain gene , 1993, Cell.

[34]  G. Sutter,et al.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. , 1991, The Journal of general virology.

[35]  A. Siccardi,et al.  IgE as Adjuvant in Tumor Vaccination , 2010 .

[36]  D. Dombrowicz,et al.  Antitumor IgE Adjuvanticity: Key Role of Fc , 2009 .

[37]  F. Codazzi,et al.  Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. , 2005, Journal of immunology.

[38]  L. Vangelista.  Current progress in the understanding of IgE-FcepsilonRI interaction. , 2003, International archives of allergy and immunology.

[39]  J. Sepúlveda,et al.  Membrane immunoglobulins are stabilized by interchain disulfide bonds occurring within the extracellular membrane-proximal domain. , 2001, Biochemistry.

[40]  J. Kinet,et al.  The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. , 1999 .